“We believe the share price will rise in absolute terms over the next 60 days,” Morgan Stanley wrote in a report this morning regarding Edwards Lifesciences Corp. EW.
:Edwards will present key data from the PARTNER Cohort A trial at the American College of Cardiology meeting in New Orleans scheduled for April 3rd. Expectations are high following positive Cohort B data, but we still see upside to the stock. Our analysis suggests the trial is likely to show non-inferiority in its primary endpoint.
“The potential to expand the addressable market into lower risk patients following success in PARTNER A should drive share price appreciation into 2H11 SAPIEN approval. We estimate that there is about a 70% to 80% or ‘very likely' probability for the scenario.”
Edwards Lifesciences closed Wednesday at $85.15.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in